These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9232254)

  • 21. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy.
    Baden LR; Katz JT; Fishman JA; Koziol C; DelVecchio A; Doran M; Rubin RH
    Transplantation; 2003 Dec; 76(11):1632-7. PubMed ID: 14702539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
    Safdar A; Rodriguez GH; Lichtiger B; Dickey BF; Kontoyiannis DP; Freireich EJ; Shpall EJ; Raad II; Kantarjian HM; Champlin RE
    Cancer; 2006 Jun; 106(12):2664-71. PubMed ID: 16691620
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients.
    Fortún J; Martín-Davila P; Moreno S; Barcena R; de Vicente E; Honrubia A; García M; Nuño J; Candela A; Uriarte M; Pintado V
    J Antimicrob Chemother; 2003 Nov; 52(5):813-9. PubMed ID: 14563893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients.
    López-Vélez R; Videla S; Márquez M; Boix V; Jiménez-Mejías ME; Górgolas M; Arribas JR; Salas A; Laguna F; Sust M; Cañavate C; Alvar J;
    J Antimicrob Chemother; 2004 Mar; 53(3):540-3. PubMed ID: 14739148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
    Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections.
    Linden P; Lee L; Walsh TJ
    Pharmacotherapy; 1999 Nov; 19(11):1261-8. PubMed ID: 10555932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety, tolerance and outcome of treatment with liposomal amphotericin B in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation.
    Kolve H; Ahlke E; Fegeler W; Ritter J; Jürgens H; Groll AH
    J Antimicrob Chemother; 2009 Aug; 64(2):383-7. PubMed ID: 19491205
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
    Linden P; Williams P; Chan KM
    Clin Transplant; 2000 Aug; 14(4 Pt 1):329-39. PubMed ID: 10945204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study.
    Cordonnier C; Mohty M; Faucher C; Pautas C; Robin M; Vey N; Monchecourt F; Mahi L; Ribaud P
    Int J Antimicrob Agents; 2008 Feb; 31(2):135-41. PubMed ID: 18162375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis.
    Sivak O; Bartlett K; Risovic V; Choo E; Marra F; Batty DS; Wasan KM
    J Pharm Sci; 2004 Jun; 93(6):1382-9. PubMed ID: 15124198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
    Borro JM; Solé A; de la Torre M; Pastor A; Fernandez R; Saura A; Delgado M; Monte E; Gonzalez D
    Transplant Proc; 2008 Nov; 40(9):3090-3. PubMed ID: 19010204
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.
    Mattiuzzi GN; Kantarjian H; Faderl S; Lim J; Kontoyiannis D; Thomas D; Wierda W; Raad I; Garcia-Manero G; Zhou X; Ferrajoli A; Bekele N; Estey E
    Cancer; 2004 Feb; 100(3):581-9. PubMed ID: 14745876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of invasive zygomycosis infections in renal transplant recipients.
    Forrest GN; Mankes K
    Transpl Infect Dis; 2007 Jun; 9(2):161-4. PubMed ID: 17462005
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): toxicity studies in rats.
    Zhang Z; Diener RM; Lipman JM
    Int J Toxicol; 2006; 25(4):285-94. PubMed ID: 16815817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Low-dose amphotericin B lipid complex for the treatment of persistent fever of unknown origin in patients with hematologic malignancies and prolonged neutropenia.
    Martino R; Subirá M; Domingo-Albós A; Sureda A; Brunet S; Sierra J
    Chemotherapy; 1999; 45(3):205-12. PubMed ID: 10224343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies.
    Martino R; Subirá M; Sureda A; Sierra J
    J Antimicrob Chemother; 1999 Oct; 44(4):569-72. PubMed ID: 10588324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Epidemiology and therapy of mycotic infections in immunocompromised host with special regard to the role of lipid formulations of amphotericin B].
    Viscoli C; Castagnola E
    Recenti Prog Med; 1999 Oct; 90(10):545-57. PubMed ID: 10592741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized double-blind study of liposomal amphotericin B (Ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients.
    Tollemar J; Ringdén O; Andersson S; Sundberg B; Ljungman P; Tydén G
    Bone Marrow Transplant; 1993 Dec; 12(6):577-82. PubMed ID: 8136741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
    Rieger CT; Dittmer M; Ostermann H
    Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of Candida infections with amphotericin B lipid complex.
    Ito JI; Hooshmand-Rad R
    Clin Infect Dis; 2005 May; 40 Suppl 6():S384-91. PubMed ID: 15809924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.